Kirsten Drejer on Symphogen sale: A public offering would have been better for everyone Although former Symphogen CEO Kirsten Drejer is happy that it was Servier that purchased Symphogen, she is disappointed that the firm didn't get the chance to prove itself on the stock exchange. Photo: Martin Slottemo Lyngstad BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT Published: 07.04.20 at 07:01 Share by email Share on LinkedIn Share on Facebook Share on Twitter Log in to read our articles Welcome to MedWatch. A part of our content is exclusive and reserved for our users. Log in Try MedWatch for 14 days. Get a trial subscription here. Do you want a trial subscription with multiple users for yourself and your colleagues? Read more about your options and find the contact information to our sales team here. Print Print Increase text size Increase text size Decrease text size Decrease text size Related articles After several cancellations in 2019, the stock exchange window is open again - analysts are divided over new listings in Denmark Symphogen CEO on strategy shift: "The capital markets did not agree with us"